AI could slash unnecessary prostate biopsies in 'Gray Zone' patients
NCT ID NCT07631806
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an artificial intelligence system that combines blood tests, lab data, and ultrasound images to better diagnose prostate cancer in men with borderline PSA levels (4-10 ng/mL). The goal is to reduce unnecessary biopsies by accurately identifying who truly has cancer. The trial involves 500 men in China and uses biopsy results as the gold standard to measure the AI's accuracy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AI-assisted diagnostic system (combines ctDNA liquid biopsy, lab data, and ultrasound images)
What this could lead to
If successful, this could provide a more accurate, non-invasive way to diagnose prostate cancer in men with borderline PSA levels, reducing unnecessary biopsies.
What could go wrong
This is an early-stage validation study at a single hospital, so results may not apply to other populations. The AI system's accuracy depends on the quality of data and may still miss some cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangxi Medical University First Affiliated Hospital
Nan'ning, Guangxi, China